Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1
The 2023 International Symposium on ALS/MND programme included joint sessions on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Planned talks covered overlapping symptoms, genetics and brain-imaging patterns, along with biomarkers such as neurofilaments and their possible use in diagnosis and clinical trials.
Why this matters
The sessions may help researchers and clinicians discuss how ALS and FTD can overlap and how disease markers could be used to monitor progression or treatment effects. These planned discussions do not change treatment for people living with ALS or FTD.
Limitations and context
This is an organisational preview published before the symposium, not a report of study results or a peer-reviewed research paper. It describes planned presentations and possible uses of imaging and biomarkers; their clinical usefulness and effect on treatment still need to be demonstrated.